Health Canada Endorsed important information on Flolan (epoprostenol sodium)

04.25.2013

Source: Health News Network

GlaxoSmithKline Inc., in consultation with Health Canada, is providing Canadians with updated information on the use of the pulmonary hypertension drug, FLOLAN®. Some vials of Sterile Diluent for FLOLAN® have been found to contain glass-related particles that may not be easily visible under normal lighting conditions. Studies indicate filtration through a 0.22 or 0.2 micron pore size filter is an effective means to remove these glass-related particles. The infusion tubing supplied by your Pharmaprix/Shoppers Drug Mart Specialty Pharmacy already incorporates a 0.2 micron filter.

There have been no reports of adverse events that could be definitively attributed to these glass-related particles in GlaxoSmithKline's safety database for FLOLAN®.

Based on this information, GlaxoSmithKline would like to advise you of the following:

  • Some vials of Sterile Diluent for FLOLAN® have been found to contain glass-related particles
  • When administering FLOLAN® you must only use the infusion tubing supplied to you by your Pharmaprix/Shoppers Drug Mart Specialty Pharmacy. This tubing already incorporates a 0.2 micron filter.
  • FLOLAN® Sterile Diluent and reconstituted FLOLAN® should be inspected for visible particles prior to use. Product containing visible particles should not be used

GlaxoSmithKline has sent a letter to healthcare professionals informing them of this safety information. A copy of that letter will be available on the Health Canada Website.

GlaxoSmithKline continues to search for improvements in the manufacturing process of the Sterile Diluent for FLOLAN® so that no vials will contain glass particles. Since the continued availability of this product is medically necessary for patients who require FLOLAN®, the use of a filter with the administration is essential for these patients.

Managing marketed health product-related side effects depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing side effects are generally presumed to underestimate the risks associated with health product treatments. Any serious or unexpected side effects in patients receiving FLOLAN® should be reported to GlaxoSmithKline Inc. or Health Canada.

GlaxoSmithKline Inc.
7333 Mississauga Road
Mississauga, Ontario
L5N 6L4
Phone: 1-800-387-7374

You can report any suspected adverse reactions associated with the use of health products to Health Canada by:

  • Calling toll-free at 1-866-234-2345; or
  • Visiting MedEffect Canada's Web page on Adverse Reaction Reporting for information on how to report online, by mail or by fax

For other health product inquiries related to this communication, please contact Health Canada at:

Health Products and Food Branch Inspectorate 
E-mail: DCVIU_UVECM@hc-sc.gc.ca
Telephone: 1-800-267-9675
Fax: 1-613-946-5636

Recent News

Subscribe

Get the latest on PH treatments, community events and more when you subscribe to our newsletter

ImagineCan_Accreditation_Trustmark_ENGFR_WHT-FNL_white.png